Liquidia Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US53635D2027
USD
36.41
-0.45 (-1.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.31 M

Shareholding (Dec 2025)

FII

3.85%

Held by 73 FIIs

DII

76.27%

Held by 21 DIIs

Promoter

6.13%

How big is Liquidia Corp.?

22-Jun-2025

As of Jun 18, Liquidia Corp. has a market capitalization of 1,161.73 million, with net sales of 14.15 million and a net profit of -127.84 million over the latest four quarters. Shareholder's funds are at 77.28 million, and total assets amount to 233.17 million.

As of Jun 18, Liquidia Corp. has a market capitalization of 1,161.73 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 14.15 million, while the sum of Net Profit for the same period is -127.84 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 77.28 million and Total Assets at 233.17 million.

View full answer

What does Liquidia Corp. do?

22-Jun-2025

Liquidia Corp. is a late-stage clinical biopharmaceutical company focused on developing innovative products, with a market cap of approximately USD 1.16 billion. As of March 2025, it reported net sales of USD 3 million and a net loss of USD 38 million.

Overview:<BR>Liquidia Corp. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of innovative products in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 1,161.73 million.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -38 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 1,161.73 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.33<BR>- Return on Equity: -271.66%<BR>- Price to Book: 23.37<BR><BR>Contact Details:<BR>- Address: P.O. Box 110085, RESEARCH TRIANGLE PARK NC: 27709<BR>- Tel: 1 919 3284400<BR>- Fax: 1 302 6365454

View full answer

Should I buy, sell or hold Liquidia Corp.?

22-Jun-2025

Is Liquidia Corp. overvalued or undervalued?

20-Sep-2025

As of May 13, 2021, Liquidia Corp. is considered a risky investment due to its high Price to Book Value of 31.19, negative EV to EBIT and EV to EBITDA ratios, and a concerning Return on Equity of -271.66%, despite having previously shown strong long-term returns compared to the S&P 500.

As of 13 May 2021, the valuation grade for Liquidia Corp. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 31.19 and negative EV to EBIT and EV to EBITDA ratios of -11.61 and -11.80, respectively. Additionally, its Return on Equity (ROE) is alarmingly low at -271.66%, further suggesting that the company is struggling to generate returns for shareholders.<BR><BR>In comparison to its peers, Liquidia Corp.'s P/E ratio of -16.20 is less favorable than Harrow, Inc. at -147.53 and Zymeworks, Inc. at -15.61, both of which also exhibit risky valuations. Notably, while Liquidia has shown impressive returns over longer periods, such as 311.85% over three years compared to the S&P 500's 70.41%, its recent performance has been disappointing, with a 1-week return of -8.63 versus the S&P 500's 1.05%. This divergence highlights the potential risks associated with the stock's current valuation.

View full answer

Is Liquidia Corp. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Liquidia Corp. shows a bullish technical trend with strong MACD and moving averages, despite mixed signals from Dow Theory and OBV, and has significantly outperformed the S&P 500 year-to-date.

As of 5 August 2025, the technical trend for Liquidia Corp. has changed from mildly bullish to bullish. The MACD is bullish on both weekly and monthly timeframes, and moving averages indicate a bullish stance on the daily timeframe. However, the Dow Theory shows a mixed signal with a mildly bearish weekly outlook and a mildly bullish monthly outlook. The Bollinger Bands are mildly bullish on both weekly and monthly timeframes, while the KST is bullish on both timeframes. The OBV presents a mildly bearish weekly signal but is bullish monthly.<BR><BR>Liquidia Corp. has demonstrated strong performance compared to the S&P 500, with a year-to-date return of 109.78% versus the S&P 500's 12.22%, and a one-year return of 148.94% compared to 17.14%. Overall, the current technical stance is bullish, supported by strong MACD and moving average indicators, despite some mixed signals from Dow Theory and OBV.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a growth in Operating Profit of 460.03%, the company declared Very Positive results in Sep 25

  • The company has declared positive results in Jan 70 after 8 consecutive negative quarters
  • RAW MATERIAL COST(Y) Fallen by -62.97% (YoY)
  • NET SALES(Q) Highest at USD 54.34 MM
  • OPERATING PROFIT(Q) Highest at USD 2.24 MM
2

Risky -

3

Rising Promoter Confidence

4

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,146 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.61

stock-summary
Return on Equity

-552.55%

stock-summary
Price to Book

142.65

Revenue and Profits:
Net Sales:
92 Million
(Quarterly Results - Dec 2025)
Net Profit:
15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.14%
0%
8.14%
6 Months
47.59%
0%
47.59%
1 Year
147.01%
0%
147.01%
2 Years
134.0%
0%
134.0%
3 Years
404.29%
0%
404.29%
4 Years
409.94%
0%
409.94%
5 Years
1214.44%
0%
1214.44%

Liquidia Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
134.04%
EBIT Growth (5y)
-34.31%
EBIT to Interest (avg)
-24.13
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.33
Sales to Capital Employed (avg)
0.22
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.52%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
142.65
EV to EBIT
-29.66
EV to EBITDA
-30.14
EV to Capital Employed
55.34
EV to Sales
45.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.62%
ROE (Latest)
-552.55%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 42 Schemes (13.74%)

Foreign Institutions

Held by 73 Foreign Institutions (3.85%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 69.43% vs 517.05% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 517.14% vs 91.59% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "92.00",
          "val2": "54.30",
          "chgp": "69.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "20.10",
          "val2": "2.20",
          "chgp": "813.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.90",
          "val2": "6.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "14.60",
          "val2": "-3.50",
          "chgp": "517.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "215.00%",
          "val2": "32.50%",
          "chgp": "18.25%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1,030.71% vs -20.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 46.30% vs -63.44% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "158.30",
          "val2": "14.00",
          "chgp": "1,030.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.80",
          "val2": "-119.10",
          "chgp": "58.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "24.20",
          "val2": "14.70",
          "chgp": "64.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-68.90",
          "val2": "-128.30",
          "chgp": "46.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-324.50%",
          "val2": "-8,666.30%",
          "chgp": "834.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
92.00
54.30
69.43%
Operating Profit (PBDIT) excl Other Income
20.10
2.20
813.64%
Interest
6.90
6.90
Exceptional Items
0.00
0.00
Consolidate Net Profit
14.60
-3.50
517.14%
Operating Profit Margin (Excl OI)
215.00%
32.50%
18.25%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 69.43% vs 517.05% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 517.14% vs 91.59% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
158.30
14.00
1,030.71%
Operating Profit (PBDIT) excl Other Income
-49.80
-119.10
58.19%
Interest
24.20
14.70
64.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-68.90
-128.30
46.30%
Operating Profit Margin (Excl OI)
-324.50%
-8,666.30%
834.18%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 1,030.71% vs -20.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 46.30% vs -63.44% in Dec 2024

stock-summaryCompany CV
About Liquidia Corp. stock-summary
stock-summary
Liquidia Corp.
Pharmaceuticals & Biotechnology
Liquidia Corp operates through it's subsidiaries, Liquidia Technologies, Inc. and RareGen, LLC (RareGen). The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using it's PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as generic Remodulin (treprostinil) for pulmonary arterial hypertension. Treprostinil can be administered as a continuous infusion through the use of an infusion pump or continuous intravenous infusion through the use of a central venous catheter.
Company Coordinates stock-summary
Company Details
P.O. Box 110085 , RESEARCH TRIANGLE PARK NC : 27709
stock-summary
Tel: 1 919 3284400
stock-summary
stock-summary
Registrar Details